Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial

Name: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial
Creator: Richard G. Langley
Published: 2026-01-26T11:29:43.644Z
Keywords: Pediatrics, Systemic Treatment, Pediatric Dermatology, Psoriasis, Phosphodiesterase Inhibitor, Early Intervention

Langley , Richard G.; Arkin, Lisa; Fiorillo, Loretta; Eichenfield, Lawrence F.; Lebwohl, Mark; Strober, Bruce; Sticherling, Michael; Swanson, Lisa; Kokolakis, Georgios; Chaudhari, Siddharth; Deignan, Cynthia; Zhang, Zuoshun; Paller, Amy

doi:10.17632/dzrgwdxhgp.1

Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial

Published: 26 January 2026| Version 1 | DOI: 10.17632/dzrgwdxhgp.1

Contributors:

,

, Michael Sticherling, Lisa Swanson,

,

Description

Supplemental data for an article published in the Journal of the American Academy of Dermatology.

Files

Funders

Amgen (United States)
California, United States

Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 Trial

Description

Files

Categories

Funders

Licence